Topics:
Medical Oncology • Myelodysplastic Syndromes
When would you use cedazuridine in combination with decitabine to treat intermediate or high risk MDS?
Given the recent FDA approval, how will the use of this oral combination fit into your practice?
https://doi.org/10.1182/blood.2019004143
Answer from: Medical Oncologist at Academic Institution
Oral cedazuridine/decitabine was approved in the US for the treatment of intermediate and high risk MDS and CMML based on its equivalent exposure to 20 mg/m2 of IV decitabine in Phase 3 study. Drug related toxicities and response rates were as would be historically expected for IV decitabine (full d...
Sign in or Register to read more